IL4 and cancer: In this process, autologous monocyte-derived mature DCs are conventionally manufactured using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) and are principally targeted against a specific cancer antigen8, 9, 10.